Iron catalyzed diastereoselective hydrogenation of chiral imines by D. Brenna et al.
Journal Name  
COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1  
Please do not adjust margins 
Please do not adjust margins 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
www.rsc.org/ 
Iron catalyzed diastereoselective hydrogenation of chiral imines 
D. Brenna,a S. Rossi, a F. Cozzia and M. Benagliaa* 
ABSTRACT: Cyclopentadienone-based iron complexes were used 
for the first time to succesfully catalyze the diastereoselective 
hydrogenation of enantiopure imines. Chiral amines, including 
valuable biologically active products, were obtained often as 
enantiomerically pure compounds. Computational studies helped 
to elucidate the chemical and stereochemical aspects of the iron-
catalyzed reaction. 
 
Strong efforts are currently devoted to the development of new 
catalysts based on non-noble transition metals, like iron and cobalt. 
In this context, an increasing number of transformations 
promoted by iron catalysts have recently been reported.1 Being 
iron a cheap and abundant element of low toxicity,2 iron-based 
catalysts are excellent candidates for application in the fine 
chemical industry. 
While the iron-promoted reduction of carbonyl groups3 has 
been extensively studied,4 the corresponding hydrogenation of 
C=N double bonds has been much less explored and only very 
limited results have been reported. In 2011 Beller5 described 
different combinations of iron cyclopentadienone-based 
catalysts6 and chiral phosphoric acids as efficient catalytic 
systems to enantioselectively reduce imines. Later, Morris7 
described for the very efficient reductions of ketones a new 
chiral iron complex, which was also used to reduce a very 
limited number of imines. Finally, in 2015 Renaud8 developed 
an achiral class of iron catalysts with enhanced reactivity in 
imine reduction compared to previous complexes.9  
Noteworthy, only Beller's and Morris' works dealt with the 
stereoselective reduction of C=N bonds,5,7 to afford chiral 
amines, despite the fact that this class of compounds are of 
enormous importance, for instance in the pharma industry.10 
With this work, we decided to explore the iron-catalyzed reduction 
of imines featuring a removable chiral auxiliary, as a simple 
methodology to obtain enantiopure amines 
We initially focused our attention on the reduction of N-(1-(R)-
phenylethyl)-imines, featuring an inexpensive chiral residue, 
readily available in both enantiomeric forms and generally 
obtained in the configurationally stable E configuration. Three 
different catalytic systems were selected for preliminary 
studies, the Knölker complex A,11 the iron complex proposed by 
Renaud, B8 and a modified Knölker-like system, C.12 These 
precatalysts required in situ activation by addition of 
trimethylamine N-oxide (TMANO), under hydrogen pressure. 
 
 
 
 
 
Figure 1: Iron pre-catalysts A-C. 
 
The catalysts were tested in the reduction of N-(1-(S)-
phenylethyl)-ethan-1-(phenyl)-1-imine 1a (Table 1). 
 
Table 1: Preliminary studies on iron-catalyzed imine reduction. 
Entry Pre-Cat. 
P (bar) 
a 
T 
(°C) 
Conv. 
(%)b 
Yield 
dr b 
1 A 30 70 41   97:3 
2 A 30 100 <5  60:40 
3 A 80 25 -  - 
4 B 30 40 26  93:7 
5 B 30 50 47 41 92:8 
6 B 30 70 98 96 93:7 
7 B 80 25 -  - 
8 C 30 70 34 30 98:2 
9 C 30 100 < 5  60:40 
10 C 80 25 -  - 
11 Fe2(CO)9 EtOH 70 14  60:40 
12c A 30 50 16  95:5 
13d A 30 50 19  92:8 
14c A 30 70 30  92:8 
15c B 30 50 -  - 
a reactions run on 0.2 mmol of imines in 2 mL of degassed ethanol. b 
conversion and d.r. evaluated by NMR on the crude reaction mixture after 
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removal of the iron particles by filtration. c 1 mol eq of salicylic acid was 
added. d 0.5 mol eq of salicylic acid was added.  
Working at 70°C, catalyst A showed a modest activity, leading 
to the desired amine 2 in high stereoselectivity (d.r. 93:7) but in 
a modest 41% yield (entry 1).The more electron rich pre-catalyst 
B (entry 6) promoted the reduction with excellent yield (up to 
96%), and diastereoisomeric ratio (up to 93:7). With complex C, 
the product was isolated with almost complete stereoselectivity 
(d.r. 98:2), but in lower yields.‡ 
At low temperature and high hydrogen pressure (entries 3, 7 
and 10) the reduction did not proceed at all, and the starting 
material was recovered unreacted. At 100°C low yields and 
modest stereoselectivities were observed, independently from 
the employed catalyst (entries 2 and 9). Under these harsh 
conditions, the release of iron from the cyclopentadienone 
ligand with concomitant generation of iron particles was 
observed. In the attempt to assess the catalytic activity of those 
particles, the reaction was run at 100°C in the presence of 
catalytic amounts of Fe2(CO)9, a notoriously thermally instable 
source of iron (entry 11). With this catalyst, conversion and 
stereoselectivity analogous to those recorded in the high 
temperature experiments were observed, thus suggesting that 
at higher temperature the reaction was promoted only by 
species generated upon catalyst decomposition. 
In the attempt to accelerate the reaction by imine  protonation 
to generate the iminium ion, the addition of an acid to the 
reaction mixture was studied. However, the reduction 
promoted by complex A in the presence of salicylic acid 
afforded the product in much lower yield and slightly but 
significantly lower stereoselectivity than in the reaction without 
acid (entries 12-14 vs 1).# Using complex B no conversion was 
observed, probably due to deactivation of the catalyst by ligand 
protonation.  
With the optimized conditions for each catalyst in our hands 
(Table 1), we explored the scope of the reaction. Imines with 
different substituents on the C-bound aromatic ring were 
reduced at 70°C in ethanol under 30 bar of hydrogen (Table 2). 
Catalyst B constantly proved to be the most active, affording the 
expected amines in modest to good yields and high 
stereoselectivity.  
With electron-donating group-substituted aryl residues 
(electron rich imines), the products were isolated in up to 65 % 
yield (entry 1 and 7), while, using electron poor imines, lower 
yields were observed, in accordance with a recently reported 
work related to the iron-catalyzed direct amination of benzyl 
alcohols (see also discussion below).13  
 
Table 2: Iron-catalyzed reduction of chiral imines: reaction scope 
 
Entrya R Cat. 
Prod 
n° 
Conv. 
(%) b 
Yield 
(%) 
drb 
1 4-OMe B 2b 65 63 92:8 
2 3-OBn B 
2c 
55 
55 >98:2
c 
3 3-OMe B 2d 49 45 97:3 
3 4-Cl A 2e 20  98:2 
4 4-Cl B 2e 53 47 >98:2 
5 4-Cl C 2e 10  98:2 
6 4-Me A 2f 20  95:5 
7 4-Me B 2f 67 65 92:8 
8 4-Me C 2f 40  87:13 
9 4-CF3 B 2g 5  67:33 
10 4-NO2 B 2h 30 27 72:28 
11 4-NO2 C 2h 10  65:35 
a reactions were performed on 0.2 mmol of imines in 2 mL of degassed 
ethanol; b conversion and d.r. were evaluated by NMR on crude mixture 
after removal of the iron particles; c NMR analysis before column 
purification showed a 95/5 d.r.. 
Having developed an efficient method to stereocontrol the 
imine C=N bond reduction, we turned our attention to the 
removal of the chiral auxiliary, an essential step to access chiral 
primary amines. With the aim to avoid also in this step the use 
of precious transition metals, commercially available (R)-1-(4-
methoxyphenyl)-ethylamine was used as a chiral auxilliary (eq. 
A, Figure 2), that would be possible to remove under mild 
oxidative degradation.14 We were please to find that good yield 
and stereoselectivity were observed in the reduction of imine 
1i. The removal was efficiently performed on the N-acetylated 
derivative, by reaction with DDQ that afforded the deprotected 
derivative in 67% overall yield (for experimental details, see the 
Supporting Information). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Synthesis of pharmaceutically active compounds. 
 
Even better results were obtained in the synthesis of advanced 
precursors of pharmaceutically relevant ingredients (eq. B, 
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Figure 2).15 Amine 2k, a direct precursor of Rasagiline, used in 
the treatment of Parkinson disease,16 was isolated in 70% yield 
as enantiomerically pure product. Amines 2c and 2d, 1-(meta 
alkoxyphenyl)-ethylamines, obtained in >97/3 d.r. (see Table 1), 
are direct precursors of several APIs, like Rivastgmine, and 
calcimimetic (R)-NPS 568,17 while chiral amine 2j, advanced 
intermediate of Tamsulosin,18 was isolated with 60 % yield and 
90:10 diasteroisomeric ratio. 
In order to better elucidate the reaction mechanism and to 
rationalize the steric course of our reactions, computational 
studies were performed. The reductions of (E) N-(1-(S)-
phenyl)ethyl imines derived from differently substituted 
acetophenones promoted by precatalyst B were studied, and 
the lowest energy transition states (TSs) leading to the 
formation of (1R,1’S) and (1S,1’S) amines, respectively, were 
located. After preliminary Monte Carlo conformational analysis, 
the lowest energy structures leading to the formation of 
(1R,1’S) and (1S,1’S) diastereoisomers, were optimized to the 
relative TSs by DFT calculations performed with GAUSSIAN 09 
program, using the hybrid B3LYP functional for all atoms except 
for iron.¥  
A superimposed cross section of the reaction profiles for the 
reduction of (E)-imines derived from acetophenone (1a), 4’-
methyl acetophenone (1f) and 4’-(trifluoromethyl) 
acetophenone (1g) is reported in Figure 3 (see supporting 
information for the complete energy profile and further data).  
 
Figure 3: Energy profile for the catalyzed reduction of imines 
(free energy values (B3LYP/6-31G(d,p) Fe(SDD) level), in kcal 
mol-1). For a 3D representation of the structures see the SI. 
 
 
Our calculation indicates that at the reaction outset, all the 
imines were coordinated by the hydrogenated form of B to give 
the corresponding adduct D. As expected, this 
substrate/catalyst coordination is energy demanding[8] and the 
hydrogen bond is significantly bent out of a linear alignment. 
The hydrogenation of imines have been described to proceed 
according to two different pathways: a synchronous  process, 
where both the hydrogen proton and the hydride are 
transferred simultaneously (as proposed by Renaud[8]); or a two 
steps process (formally the protonation of imine nitrogen atom 
followed by the transfer of the hydride) as reported by 
Berkessel for N-t-butyl substituted aromatic keto-imines.[19] 
Analysis of the diastereoisomeric TS's involving the Re and Si 
faces (TSRe and TSSi) revealed that the transfer of the hydride 
from the iron atom to the carbon atom happens when the 
proton transfer from the hydroxy group of hydrogenated 
catalyst B to the imine nitrogen has already almost completely 
occurred in a mechanism that we can define concerted but  
asynchronous (see the SI, Figure S6). Indeed, a clearly defined 
two-steps mechanism could be considered as an exception, as 
already remarked.19 Finally, after the transfer of both hydrogen 
atoms to the imine, the resulting adduct E is formed and 
dissociates to afford the free amine and pre-catalyst B, which 
will re-enter the catalytic cycle once that it has taken up a new 
molecule of hydrogen.  
Looking at the energy values in Figure 3, the TSs at lower energy 
are those responsible of the hydride transfer onto the Re-face 
of the (1S’)-imines, and lead to the favored (1S,1’S)-isomers, in 
qualitative agreement with the experimental data. Moreover, 
electron-rich imines, that are reduced in higher yields, have 
indeed TSs of lower energy than those of electron poor 
counterparts (4-CH3Ph  ̴ Ph < 4-CF3Ph). Although the calculations 
well rationalize the diastereoselectivity and the order of 
reactivity of the imines, the poor or inexistent reactivity of 
electron poor imines is not easily accounted for. A possible 
explanation could be that N-protonation to generate a more 
reactive iminium ion (see adduct D), is more facilitated with 
electron rich imines, due to their nitrogen higher basicity. The 
observation that the OH-N distance in adduct D for the CF3-
substituted imine is longer than in the Me-substituted substrate 
can tentatively lend support to this interpretation (Figure 3). 
In conclusion, we have reported the first iron-catalyzed 
diastereoselective reduction of chiral imines; the method leads 
to the formation of chiral amines, often isolated as 
enantiomerically pure products. The synthesis of advanced 
intermediates of highly valuable APIs demonstrates the 
possibility to apply iron catalysis in the fine chemical industry. 
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University of Milan for a postdoctoral fellowship. 
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‡ The reaction tested in other solvents, including toluene, anisole, 
glycols and water, did not work or gave very low yields. 
# The use of other acidic additives did not lead to any appreciable 
different result. 
¥ The SDD functional with default parameters was used for iron 
to account for the influence of occupied d-orbitals. The geometry 
of intermediate complexes and transition states was optimized in 
the gas phase without geometry constraints using the 6-31G(d,p) 
basis set for all atoms except for iron, which was described by the 
SDD basis set (for further details see SI). 
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